Search

Your search keyword '"Miao, L."' showing total 272 results

Search Constraints

Start Over You searched for: Author "Miao, L." Remove constraint Author: "Miao, L." Database Unpaywall Remove constraint Database: Unpaywall
272 results on '"Miao, L."'

Search Results

5. Preliminary Results of Phase II Study on Preoperative Intensity-Modulated Radiotherapy with Concurrent Tyrosine Kinase Inhibitor for Patients with Non-Metastatic Extremity and Trunk Soft Tissue Sarcoma

8. LBA58 Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study

13. 7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial

16. VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

19. Comprehensive epigenomic profiling of human alveolar epithelial differentiation identifies key epigenetic states and transcription factor co-regulatory networks for maintenance of distal lung identity

22. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

23. P51.03 Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial

26. Can improved nutrition for Atlantic salmon in freshwater increase fish robustness, survival and growth after seawater transfer?

27. Spin-valley locking and bulk quantum Hall effect in a noncentrosymmetric Dirac semimetal BaMnSb2

32. Strain-stabilized superconductivity

39. Inhomogeneous ferromagnetism mimics signatures of the topological Hall effect in SrRuO3 films

41. LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)

Catalog

Books, media, physical & digital resources